Overview

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of eribulin mesylate in subjects with soft tissue sarcoma who received at least one standard chemotherapy (an anthracycline or an ifosfamide monotherapy or a combination therapy).
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Co., Ltd.